Epigenomic ctDNA profiling identifies PDAC subtypes and improves prognostication over tissue-based methods in metastatic diseaseCan a blood test predict pancreatic cancer subtypes better than tissue samples?

This multi-institutional cohort study investigated the utility of epigenomic profiling of circulating tumor DNA (ctDNA) for subtyping pancreatic ductal adenocarcinoma (PDAC). The population consisted of patients with metastatic PDAC and patient-derived xenografts. The primary objective was to identify PDAC subtypes, specifically classical and basal-like, using this non-invasive approach compared to traditional tissue-based subtyping.

The main results indicated that epigenomic signatures successfully identified PDAC subtypes from plasma samples. The study reported that the epigenomic profiling method (PIES) was concordant with tissue-based labels and effectively captured transcriptional subtype heterogeneity. Furthermore, prognostication was improved when using this method over tissue-based subtyping. Specific absolute numbers, p-values, or confidence intervals were not reported in the available data.

Safety and tolerability data were not reported, as adverse events, serious adverse events, discontinuations, and general tolerability metrics were absent from the study records. The study is characterized as a proof-of-concept, which inherently limits the certainty of the findings. No specific limitations beyond the proof-of-concept nature were detailed, and funding or conflicts of interest were not reported.

The practice relevance of this work lies in its potential to enable transcriptional subtyping and inform therapeutic decisions in pancreatic cancer. However, given the proof-of-concept status, clinicians should interpret these results conservatively. The study does not yet support widespread adoption without further validation in larger, randomized trials.